www.orphazyme.com

Company Registration No. 32266355

Notice to convene Annual General Meeting

Copenhagen, Denmark, March 3, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the Company’s Annual General Meeting will be held on:

Thursday, March 25, 2021 at 5:00 PM (CET)

at the Company’s address Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark.

In order to protect the health and safety of all, reduce the risk of COVID-19 spreading, and given the Danish government’s restrictions on assembly, we strongly recommend that shareholders refrain from attending the Annual General Meeting in person and instead exercise their shareholder rights by giving proxy to the Board of Directors or by voting by correspondence prior to the Annual General Meeting.

The notice to convene the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors and Appendix 2: Revised Remuneration Policy, is attached.

Additional information about the Annual General Meeting is available on the Company’s website: https://orphazyme.gcs-web.com/annual-general-meeting-0

For additional information, please contact

Orphazyme A/S

About Orphazyme A/S 
Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases. The company is harnessing amplification of Heat-Shock Proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction, including lysosomal storage diseases and neuromuscular degenerative diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), Inclusion Body Myositis (IBM) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme’s shares are listed on Nasdaq U.S. (ORPH) and Nasdaq Copenhagen (ORPHA). 

About arimoclomol 
Arimoclomol is an investigational drug candidate that amplifies the production of Heat-Shock Proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is administered orally and has now been studied in seven phase 1, four phase 2 and one pivotal phase 2/3 trial. Arimoclomol is in clinical development for NPC, Gaucher Disease, sIBM, and ALS. Arimoclomol has received orphan drug designation (ODD) for NPC, IBM, and ALS in the US and EU. Arimoclomol has received fast-track designation (FTD) from the U.S. Food and Drug Administration (FDA) for NPC, IBM and ALS. In addition, arimoclomol has received breakthrough therapy designation (BTD) and rare-pediatric disease designation (RPDD) from the FDA for NPC.

Page 1 of 2

Forward-looking statement 

This company announcement may contain certain forward-looking statements, including in respect of the anticipated commercialization of arimoclomol. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof . Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements, including the risk that applicable regulatory authorities fail to approve arimoclomol on the anticipated timeline or at all. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Attachments

Page 2 of 2

Exhibit 99.2

To the shareholders of Orphazyme A/S

The Board of Directors hereby convenes the Annual General Meeting of Orphazyme A/S, CVR no. 32 26 63 55 (the “Company”), to be held on Thursday, March 25, 2021 at 5:00 PM (CET), at the Company’s address Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark.

In order to protect the health and safety of all, reduce the risk of COVID-19 spreading, and given the Danish government’s restrictions on assembly, we strongly recommend that shareholders refrain from attending the Annual General Meeting in person and instead exercise their shareholder rights by giving proxy to the Board of Directors or by voting by correspondence prior to the Annual General Meeting.

Agenda

Items on the agenda, including complete proposals:

Item 1: The Board of Directors’ election of the Chairman of the meeting

The Board of Directors will elect the Chairman of the Annual General Meeting.  

Item 2: The Board of Directors’ report on the Company’s activities in the past financial year

The Board of Directors proposes that the report on the Company’s activities in 2020 be noted by the Annual General Meeting.

Item 3: Presentation and adoption of the annual report 2020

The Board of Directors proposes that the Company’s annual report 2020 be adopted.

Item 4: Allocation of loss according to the adopted annual report 2020

The Board of Directors proposes that the loss related to the financial year 2020 amounting to approximately DKK 633.2 million be carried forward.

Item 5: Resolution to grant discharge of liability to the Board of Directors and the Executive Management
The Board of Directors proposes that the Annual General Meeting grant discharge of liability to the members of the Board of Directors and the Executive Management for liability towards the Company in relation to the approved annual report 2020.

Page 1 of 7

Item 6: Presentation of the Company’s remuneration report for 2020

The Company has prepared a remuneration report for 2020, which according to applicable legislation is presented to the Annual General Meeting for an advisory vote.

The remuneration report has been prepared in accordance with the requirements of section 139b of the Danish Companies Act and includes information on remuneration awarded or due to the members of the Board of Directors and the Executive Management of the Company concerning the financial year 2020.

The remuneration report for 2020 is available on the Company’s website, https://orphazyme.gcs-web.com/corporate-governance/governance-documents.

The Board of Directors proposes that the Annual General Meeting approves the Company’s remuneration report for 2020 in the advisory vote.

Item 7: Approval of remuneration of the Board of Directors for the current financial year
The Board of Directors proposes that the following remuneration level to the Board of Directors for 2021 be approved by the Annual General Meeting:

The remuneration level for the Board of Directors is maintained at the same level as for 2020 as approved by the Extraordinary General Meeting on September 21, 2020.

The members of the Board of Directors receive annual supplementary fees for their work in the Company’s Audit Committee, Remuneration Committee, Nomination Committee, and Science Committee. The Board of Directors proposes that the Annual General Meeting approve the following supplementary fees for 2021 for committee work:

Page 2 of 7

The supplementary fees for committee work are maintained at the same level as for 2020 as approved by the Extraordinary General Meeting on September 21, 2020.

In addition, members of the Board of Directors may receive a fixed travel allowance as determined by the Board of Directors and be reimbursed for expenses in connection with board meetings (e.g. related to travel and accommodation). Further, the Company may pay or reimburse social security duties and

similar taxes imposed by public authorities in relation to board fees.

Further, the members of the Board of Directors will receive share-based remuneration for 2021 in the form of restricted share units (“RSUs”) through an annual grant corresponding to 50% of each Board member’s fixed annual base fee, such base fee to include additional base fees to the Chairman and Deputy Chairman but excluding any additional fees for committee membership.

As announced in company announcement no. 72/2020 of December 10, 2020, the Company’s CEO had resigned and the Company initiated a search for a new CEO. The Company has, as announced in company announcement no. 05/2021 of March 1, 2021, appointed Christophe Bourdon as the Company’s CEO, effective as of April 1, 2021. In order to ensure continuity going forward, the Company’s Chairman of the Board of Directors, Georges Gemayel, is assisting the Executive Management of the Company in an interim period with ad-hoc tasks, until the appointment of Christophe Bourdon as CEO is effective. As a result hereof the Board of Directors proposes that the Annual General Meeting approves an ad-hoc fee to the Chairman of the Board of Directors for 2021 of EUR 88,605 and an additional grant of RSUs equal to 100% of the annual grant of RSUs for 2021. The remuneration for the ad hoc tasks of the Chairman are maintained at the same level as for 2020.

Item 8: Election of members to the Board of Directors

Pursuant to Article 8.1 of the Articles of Association, the Board of Directors shall consist of not less than six and not more than nine members elected by the general meeting. The members of the Board of Directors elected by the general meeting are elected for a term of one year pursuant to Article 8.2 of the Articles of Association. Re-election of board members may take place.

The Board of Directors proposes re-election for a one-year term of the following members of the Board of Directors elected by the general meeting: Georges Gemayel, Bo Jesper Hansen, Anders Hedegaard, Carrolee Barlow, Catherine Moukheibir, Martijn Kleijwegt, Martin Bonde and Rémi Droller. In addition, the Board of Directors proposes that the general meeting elect Stephanie Okey as new member of the Board of Directors. The current board member Sten Verland is not seeking re-election.

Please see Appendix 1 for a description of the nominated candidates’ qualifications and positions, including information about other executive/management functions held by the candidates in Danish and foreign companies.

Item 9: Election of auditor

In accordance with the Audit Committee’s recommendation, the Board of Directors proposes re-election of EY Godkendt Revisionspartnerselskab, CVR no. 30 70 02 28, as the Company’s auditor. The Audit Committee’s recommendation has not been influenced by third parties, nor has it been subject to any contractual obligation restricting the Annual General Meeting’s choice of certain auditors or audit firms.

Item 10: Authorization to acquire treasury shares

In order to continuously provide the Company with the necessary flexibility to raise new capital through alternative transaction structures, the Board of Directors proposes to renew the current authorization to the Board of Directors to acquire treasury shares in the period until March 25, 2026, on one or more occasions, with a total nominal value of up to 10% of the share capital of the Company from time to time, subject to the Company’s holding of treasury shares after such acquisition does not exceed 20% of the

Page 3 of 7

Company’s share capital. The consideration may not deviate more than 10% from the official price quoted on Nasdaq Copenhagen at the time of acquisition.  

Item 11: Any proposals from the Board of Directors

Item 11.1: Approval of adjustments to the Company’s Remuneration Policy

The Board of Directors proposes that the Annual General Meeting approves certain adjustments to the Company’s Remunerations Policy as adopted by the Board of Directors.

The revised Remuneration Policy includes the following material changes:

The revised Remuneration Policy is attached as Appendix 2 and is available on the Company’s website, https://orphazyme.gcs-web.com/annual-general-meeting-0.

Item 11.2: Amendments to Article 3.1 of the Articles of Association

By decisions of September 28, 2020, the Board of Directors has partly exercised the authorization in Article 3.1 of the Articles of Association to increase the Company’s share capital without pre-emption rights for existing shareholders following which a nominal value of DKK 7,616,146 of the authorization has been issued.

In order to continuously provide the Company with the necessary flexibility to raise new capital, the Board of Directors proposes that the authorization in Article 3.1 be reset and extended until March 25, 2026. Consequently, the Board of Directors proposes that Article 3.1.1 be deleted from the Articles of Association and that Article 3.1 of the Articles of Association be amended as follows:

“In the period until 25 March 2026, the Board of Directors is authorised to increase the Company’s share capital in one or more issues of new shares without pre-emption rights for the Company’s existing shareholders by up to a nominal amount of DKK 6,989,767. The capital increase shall take place at market price as determined by the Board of Directors and shall be effected by cash payment, debt conversion or contribution in kind.”

Item 11.3: New Article 3.5 of the Articles of Association

The Board of Directors proposes to adopt a new Article 3.5 of the Articles of Association in order to authorize the Board of Directors to increase the Company’s share capital without pre-emption rights for the Company’s existing shareholders in connection with the issue of new shares to members of the Board of Directors, executives and/or employees of the Company. The capital increase may take place below market price.

The Board of Directors proposes that a new Article 3.5 be included as follows:

“In the period until 25 March 2026, the Board of Directors is authorised to increase the Company’s share capital in one or more issues without pre-emption rights for the Company’s existing shareholders by up to a nominal amount of DKK 1,300,000 in connection with the issue of new shares to members of the Board of Directors, executives and/or employees of the Company. The new shares shall be issued against cash payment at a subscription price to be determined by the Board of Directors, which may be below the market price.”

Page 4 of 7

Further, the Board of Directors proposes a total cap of nominally DKK 2,000,000 for the capital increase authorizations set out in Article 3.2 and the new Article 3.5. Consequently, the following new Article 3.6 is proposed:

“The authorisations granted to the Board of Directors pursuant to Articles 3.2 and 3.5 can in the aggregate only be exercised to increase the share capital by a maximum nominal amount of DKK 2,000,000.”

If the new Article 3.5 and Article 3.6 is approved, the current Article 3.5 will be renumbered to Article 3.7, and the new Article 3.7 will be amended as follows:

“New shares issued pursuant to Articles 3.1, 3.2, 3.3, 3.4 and 3.5 shall be fully paid up, issued in the name of the holder and shall be recorded in the name of the holder in the Company’s register of shareholders, shall be negotiable instruments and shall in every respect carry the same rights as the existing shares. The Board of Directors is authorised to lay down the terms and conditions for capital increases pursuant to the above authorisations and to make any such amendments to the Company’s Articles of Association as may be required as a result of the Board of Directors’ exercise of said authorisations.”

Adoption requirements

The proposals under item 11.2-11.3 on the agenda shall be passed by at least two-thirds of the votes cast as well as at least two-thirds of the share capital represented at the Annual General Meeting, cf. Article 7.2 of the Articles of Association.

All other proposed resolutions on the agenda shall be passed by a simple majority of votes cast, cf. Article 7.1 of the Articles of Association. The Remuneration Report is subject to an advisory vote.

Share capital and shareholders’ participation and voting rights

The Company’s nominal share capital is 34,948,837, divided into shares of DKK 1 each or multiples thereof. Each share of the nominal value of DKK 1 carries one vote.

The right of a shareholder to attend and vote at a general meeting is determined by the shares held by the shareholder at the record date. The record date is Thursday, March 18, 2021.

The shares held by each shareholder at the record date are calculated based on the registration of the number of shares held by the shareholder in the Company’s register of shareholders as well as any notification of ownership received by the Company for the purpose of registration in the Company’s register of shareholders, but which has not yet been registered.

Notification of participation

Shareholders, who are entitled to attend the Annual General Meeting and wish to attend the Annual General Meeting must notify the Company of participation no later than on Friday, March 19, 2021 at 11:59 PM (CET). The registration form is available on the Company’s website, https://orphazyme.gcs-web.com/annual-general-meeting-0.

Notification of participation may be provided as follows:

A shareholder or a proxy may participate in the Annual General Meeting together with an adviser, provided that notification of the adviser’s participation has been provided.

Page 5 of 7

A confirmation of registration will be sent by email to the email address provided by the shareholder upon registration of participation. The electronic admission card must be presented at the Annual General Meeting either via smartphone/tablet or as a printed version. Further, it will be possible for the shareholder to collect the admission card at the venue for the Annual General Meeting upon presentation of appropriate identification. Ballot papers will be handed out at the registration desk at the venue.

How to submit a proxy

Proxy forms must be received by Computershare A/S no later than on Friday, March 19, 2021. The proxy form is available on the Company’s website, https://orphazyme.gcs-web.com/annual-general-meeting-0.

Proxies may be submitted as follows:

How to vote by correspondence

Shareholders who are entitled to participate in the Annual General Meeting are also entitled to vote by correspondence. Votes by correspondence must be received by Computershare A/S no later than on Wednesday, March 24, 2021, at 3:00 PM (CET). The voting form (which is the same form used for granting a proxy) is available on the Company’s website, https://orphazyme.gcs-web.com/annual-general-meeting-0.

Voting by correspondence may be submitted as follows:

Additional information on the website

Until and including the day of the Annual General Meeting, the following information regarding the Annual General Meeting will be available on the Company’s website, www.orphazyme.com:

Registration of admission cards at the Annual General Meeting on Thursday, March 25, 2021, will open at 4:00 PM (CET).

Questions from the shareholders

Shareholders may ask questions to the Board of Directors and the Executive Management at the Annual General Meeting. Questions regarding the agenda and documents concerning the Annual General Meeting

Page 6 of 7

may be submitted in writing prior to the Annual General Meeting by ordinary mail to Orphazyme A/S, Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark, or by email to contact@orphazyme.com.

Personal data

With regards to collection and processing of personal data, reference is made to the Company’s information sheet on data protection in connection with the Annual General Meeting, which is available on the Company’s website, https://orphazyme.gcs-web.com/annual-general-meeting-0.

Language

The Annual General Meeting will be held in English in accordance with Article 4.7 of the Company’s Articles of Association.

How to get there

The Annual General Meeting will be held at the Company’s address Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark, which can be reached by car or public transport.

Copenhagen, March 3, 2021

The Board of Directors

Page 7 of 7

Exhibit 99.3

Appendix 1: Candidates for the Board of Directors

*Listed companies

Special competences
Dr. Gemayel’s qualifications to sit on the Board of Directors include his significant management and executive experience in the global pharmaceutical industry.

Other management duties
Georges Gemayel is currently Chairman of the Board of Directors of Dynacure SAS, Enterome SA, and OxThera AB and a member of the Board of Directors of Supernus Pharmaceuticals Inc. (publ)*.

Previous positions
Georges Gemayel has previously been Chairman of the Board of Directors of Dimension Therapeutics Inc. (publ), Epitherapeutics ApS, Vascular Magnetics Inc., and Syndexa Pharmaceuticals Inc. as well as a member of the Board of Directors of NPS Pharmaceuticals Inc. (publ), Raptor Pharmaceuticals Corp. (publ), Prosensa N.V. (publ), Adolor Corp. (publ), and Momenta Pharmaceuticals Inc. (publ).

Educational background
Georges Gemayel holds a Master and a PhD in Pharmacology from Paris-Sud University and a Docteur d’Exercice en Pharmacie from the St. Joseph University.

Special competences
Dr. Hansen's extensive experience in orphan drugs, both from the operations and supervisory point of view and his broad and current know-how of the biotechnology environment makes him a qualified member of the Board of Directors.

Other management duties
Bo Jesper Hansen is currently Chairman of the Board of Directors of Laborie Inc., Innoventa Medica ApS, and Karo Pharma AB and a member of the Board of Directors of Ascelia Pharma AB and Reapplix A/S.

Previous positions
Bo Jesper Hansen has previously been Chairman of the Board of Directors and a member of the Executive Management of Swedish Orphan Biovitrum AB (publ), Chairman of the Board of Directors of Ablynx NV, Topotarget A/S (publ) (dissolved by merger), Karolinska Development AB (publ) and a member of the Board of Directors of Newron Pharmaceuticals SpA, CMC Sweden AB, Hyperion Therapeutics Inc. (publ) (dissolved following acquisition), Gambro AB, Inspyr Inc. (publ), Zymenex Holding A/S, Zymenex A/S, ACE Bioscience A/S, Mipsalus Holding ApS, MipSalus ApS, Azanta A/S, and Reapplix A/S.

Educational background

Bo Jesper Hansen holds an MD and PhD in Medicine from the University of Copenhagen.

Page 1 of 5

Special competences
Mr. Hedegaard is a sitting Chief Executive Officer of a publicly listed company. His extensive knowledge of the healthcare industry, both in product development and commercialization, makes him a qualified member of the Board of Directors.

Other management duties
Anders Hedegaard is currently Chief Executive Officer of Rodenstock Group and Chairman of the Board of Directors of Rodenstock Danmark A/S and ALK-Abelló A/S (publ)*.

Previous positions
Anders Hedegaard has previously been Chairman of the Board of Directors of GN Otometrics A/S, Aktieselskabet af 1. juni 2011 I, and BN Washington D.C. Holding A/S as well as a member of the Board of Directors of the Confederation of Danish Enterprise, Hearing Instrument Manufacturers Software Association A/S, HIMSA II A/S, Origio A/S and certain companies in or associated with the Bavarian Nordic Group. Further, Anders Hedegaard has previously been Chief Executive Officer of GN Store Nord A/S (publ), GN Hearing A/S, and Bavarian Nordic A/S and a member of the Executive Management of ALK-Abelló A/S and FOSS A/S as well as international marketing director at Novo Nordisk A/S.

Educational background
Anders Hedegaard holds a Master of Science in Chemical Engineering and Biochemistry from the Technical University of Denmark.

Special competences
Dr. Barlow’s qualifications to sit on the Board of Directors include her renowned expertise in neuroscience and neurodegeneration, the treatment of rare and neurological diseases, and the clinical development of new therapies.

Other management duties
Carrolee Barlow is currently member of the Board of Directors of Supernus Pharmaceuticals Inc. (publ)* and Chief Medical Officer of ESCAPE Bio Inc. as well as member of the scientific and/or clinical advisory board of Neurametrix Inc., Kainos Medicine (publ)* and Silverstein Foundation.

Previous positions
Carrolee Barlow has previously been member of the Board of Directors of Parkinson’s Institute and Clinical Center as well as Chief Executive Officer of Parkinson’s Institute and Chief Scientific and Chief Medical Officer of BrainCells Inc.

Educational background
Carrolee holds a Master from the University of Utah School of Medicine and a PhD in Molecular and Development Biology from the Karolinska Medical Nobel Institute.

Page 2 of 5

Special competences
Ms Moukheibir's experience in the pharmaceutical and banking industries and her successful track record in leading Audit Commitees of publicly traded companies makes her a qualified member of the Board of Directors.

Other management duties
Catherine Moukheibir is currently Non-Executive Board Member and Chair of the Audit Committee at CMR Surgical and a member of the Board of Directors of Genkyotex SA (publ)*, Ironwood Pharmaceuticals, Inc., and Kymab Ltd.

Previous positions
Catherine Moukheibir has previously been a member of the Executive Management for Innate Pharma Inc (publ) and MedDay Pharmaceuticals SA, Chairman of the Board of Directors of Creabilis and MedDay Pharmaceuticals SA and a member of the Board of Directors in Zealand Pharma A/S (publ), Ablynx NV (publ), Cerenis Therapeutics SA (publ), and Octoplus NV.

Educational background

Catherine Moukheibir holds a Master in Economics and a MBA degree, both from Yale University.

Special competences
Mr. Kleijwegt is qualified to serve on the Board of Directors given his experience as a major European venture-capital investor, his experience in the pharmaceutical industry, and his service on the Boards of Directors of other biopharmaceutical companies.

Other management duties
Martijn Kleijwegt is currently Founder and Managing Partner at LSP Management Group BV and a member of the Board of Directors of AM Pharma BV, Kiadis Pharma N.V. (publ)*, OxThera AB, Eloxx Pharmaceuticals Ltd., Arvelle Therapeutics BV, Vico Therapeutics Holding BV, and Pharvaris BV.

Previous positions
Martijn Kleijwegt has previously been a member of the Board of Directors of Prosensa N.V. (publ).

Educational background

Martijn Kleijwegt holds a Master’s degree in Economics from the University of Amsterdam.

Page 3 of 5

Special competences
Dr. Bonde's qualifications to sit on the Board of Directors include his executive experience and in-depth knowledge of the biotechnology environment in the Nordic countries.

Other management duties
Martin Bonde is currently Chief Executive Officer of Inthera Bioscience AG. Martin Bonde is also a member of Board of Directors of Visiopharm A/S, BioInnovation Institute Fonden and BII Holdings A/S, Chief Executive Officer of Bohrs Tower ApS as well as a member of the Board of Directors and the Executive Management of Biotopix ApS.

Previous positions
Martin Bonde has previously been the Chairman of the Board of Directors of DANSK BIOTEK and a member of the Executive Management of Vaccibody AS, Epitherapeutics ApS, and Entrepreneur-in-Residence at BiOrigin ApS, a Novo Seeds company.

Educational background
Martin Bonde holds a Graduate Diploma in Business Administration from Copenhagen Business School, a Master of Science, and a PhD in Chemical Engineering from the Technical University of Denmark.

Special competences
Mr. Droller's extensive experience as a biotechnology investor and his proven track-record in negotiating several successful transactions make him a qualified member of the Board of Directors.

Other management duties
Rémi Droller is currently Managing Partner of Kurma Partners SA and member of the Board of Directors of Dynacure SAS, ImCheck Therapeutics SAS, OxThera AB, AM Pharma BV, Pharvaris BV, Flamingo Therapeutics BV, and Vico Therapeutics BV.

Previous positions
Rémi Droller has previously been Chairman of the Board of Directors of Step Pharma SAS and a member of the Board of Directors of Prosensa N.V. (publ), and Onxeo SA (publ).

Educational background

Rémi Droller holds a Master in Molecular Biology from Université Pierre et Marie Curie and a Master in Finance and Management of Innovation from AgroParisTech.

Page 4 of 5

Special competences
Stephanie Okey has extensive launch and commercialization experience including nine rare and orphan disease therapeutics; two with REMS designation, and four large market therapeutic agents. Ms Okey’s specific expertise is in the launch and sustainable commercialization life cycle of bringing therapeutic agents to health care providers, health care stakeholders, and patients in a patient-centric business model.

Other management duties
Stephanie Okey currently serves as an independent member of the Board of Directors of PTC Therapeutics (publ)*, Albireo BioPharma (publ)*, and Crinetics Pharmaceuticals (publ)*.

Previous positions
Stephanie Okey has served in various positions of increasing responsibility in the biopharmaceutical industry for more than 30 years. After beginning her career at Bristol Myers Squibb (publ), she joined Genentech, Inc., growing rare orphan diseases markets and large markets for 7 years. Ms Okey’s management and leadership experience during her 19-year tenure at Genzyme, A Sanofi Company, included serving as Senior Vice President, Head of North America, Rare Diseases, and U.S. General Manager, Rare Diseases prior to her retirement in 2015. In addition, she previously served as a member of the Board of the California Life Sciences Association.

Educational background

Stephanie Okey holds a Bachelor of Science degree in Zoology from The Ohio State University and an M.S. in Immunology and Medical Microbiology from Wright State University.

Page 5 of 5

Exhibit 99.4

Remuneration Policy

Orphazyme A/S

Short-term cash incentive program

Share-based incentive program

This Remuneration Policy has been adopted by the Board of Directors on March 1, 2021 and has been approved at the Company’s annual general meeting on March 25, 2021.